The Lancet Confirms Sputnik V Vaccine's Effectiveness
The Gamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation and the Russian Direct Investment Fund announced on February 2, 2021, that The Lancet medical journal published interim results of a Phase III clinical trial of Sputnik V, confirming the vaccine's high efficacy and safety.
According to the peer-reviewed study's results, the Sputnik V vaccine provided full protection against severe cases of the novel coronavirus infection. It generated a robust humoral and cell-mediated immune response.
In the interim efficacy analysis of the randomized, double-blind, placebo-controlled clinical trial, where data on 19,866 volunteers were included in the efficacy analysis, the two-dose treatment of Sputnik V administered 21 days apart demonstrated efficacy of 91.6% against COVID-19. The calculation is based on the analysis of 78 confirmed cases of COVID-19 identified in the placebo group (62 cases) and the vaccine group (16 cases).
The Sputnik V vaccine is based on a well-studied human adenoviral vectors platform.
Alexander Gintsburg, Director of the Gamaleya Research Institute of Epidemiology and Microbiology, commented in a press statement, "The Russian vaccine's safety and high efficacy are shown by the hard scientific data presented, and I congratulate the entire team of Gamaleya National Research Center for this monumental achievement. Several vaccines have already been created based on human adenoviruses, and this tool is one of the most promising for the development of new vaccines in the future."
Sputnik V is currently registered in 16 countries: Russia, Belarus, Serbia, Argentina, Bolivia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, United Arab Emirates, Iran, the Republic of Guinea, Tunisia, and Armenia.